Evidence map›Paper›PMID 35448377›Full record

ArticleMembranes2022

MXene (Ti

Reem S Azam, Dema A Almasri, Radwan Alfahel, Alaa H Hawari, Mohammad K Hassan, Ahmed A Elzatahry, Khaled A Mahmoud

Abstract read
In one paragraph

Article in Membranes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Reem S AzamQatar Environment and Energy Research Institute (QEERI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 34110, Qatar.
Dema A AlmasriQatar Environment and Energy Research Institute (QEERI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 34110, Qatar.ORCID 0000-0003-1258-2266
Radwan AlfahelDepartment of Civil and Architectural Engineering, Qatar University, Doha P.O. Box 2713, Qatar.
Alaa H HawariDepartment of Civil and Architectural Engineering, Qatar University, Doha P.O. Box 2713, Qatar.
Mohammad K HassanCenter for Advanced Materials, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-5316-2463
Ahmed A ElzatahryMaterials Science and Technology Program, College of Arts and Sciences, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-7291-5723
Khaled A MahmoudQatar Environment and Energy Research Institute (QEERI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha P.O. Box 34110, Qatar.ORCID 0000-0003-1246-4067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obstacles in the membrane-based separation field are mainly related to membrane fouling. This study involved the synthesis and utilization of covalently crosslinked MXene/cellulose acetate mixed matrix membranes with MXene at different concentrations (CCAM-0% to CCAM-12%) for water purification applications. The membranes' water flux, dye, and protein rejection performances were compared using dead-end (DE) and crossflow (CF) filtration. The fabricated membranes, especially CCAM-10%, exhibited high hydrophilicity, good surface roughness, significantly high water flux, high water uptake, and high porosity. A significantly higher flux was observed in CF filtration relative to DE filtration. Moreover, in CF filtration, the CCAM-10% membrane exhibited 96.60% and 99.49% rejection of methyl green (MG) and bovine serum albumin (BSA), respectively, while maintaining a flux recovery ratio of 67.30% and an irreversible fouling ratio at (

Indexed as

antifoulingcrossflowmembrane filtrationMXene

Identifiers

PMID35448377
PMCPMC9027356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.